Document Detail

Photodynamic therapy as adjunctive therapy for morpheaform basal cell carcinoma.
MedLine Citation:
PMID:  21879201     Owner:  NLM     Status:  MEDLINE    
The authors decided to evaluate the possible use of methyl-aminolevulinate photodynamic therapy (MAL-PDT) as adjunctive therapy for morpheaform basal cell carcinoma prior to standard surgical excision in order to reduce tumor size and volume and to facilitate surgical treatment. It was observed that MAL-PDT may be an option as an adjunctive therapy prior to standard surgical excision of morpheaform basal cell carcinoma, leading to less invasive surgery.
T Torres; I Fernandes; V Costa; M Selores
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta dermatovenerologica Alpina, Pannonica, et Adriatica     Volume:  20     ISSN:  1581-2979     ISO Abbreviation:  Acta Dermatovenerol Alp Pannonica Adriat     Publication Date:  2011  
Date Detail:
Created Date:  2011-08-31     Completed Date:  2012-01-19     Revised Date:  2014-05-30    
Medline Journal Info:
Nlm Unique ID:  9422563     Medline TA:  Acta Dermatovenerol Alp Pannonica Adriat     Country:  Slovenia    
Other Details:
Languages:  eng     Pagination:  23-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aminolevulinic Acid / analogs & derivatives
Carcinoma, Basal Cell / drug therapy*,  surgery
Chemotherapy, Adjuvant
Chromosomes, Artificial, Bacterial
Facial Neoplasms / drug therapy,  surgery
Photosensitizing Agents / therapeutic use
Skin Neoplasms / drug therapy*,  surgery
Reg. No./Substance:
0/Photosensitizing Agents; 0/methyl 5-aminolevulinate; 88755TAZ87/Aminolevulinic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single...
Next Document:  Tufted hair folliculitis: a case report and literature review.